| Ownership structures and R&D in Europe: the good institutional investors, the bad and ugly impatient shareholders O Brossard, S Lavigne, M Erdem Sakinç Industrial and Corporate Change 22 (4), 1031-1068, 2013 | 150 | 2013 |
| Financialization and productive models in the pharmaceutical industry M Montalban, ME Sakinç Industrial and Corporate Change 22 (4), 981-1030, 2013 | 118 | 2013 |
| US pharma's financialized business model W Lazonick, M Hopkins, K Jacobson, ME Sakinç, Ö Tulum Institute for New Economic Thinking Working Paper Series, 2017 | 83 | 2017 |
| Why stock buybacks are dangerous for the economy W Lazonick, ME Sakinç, M Hopkins HAL Post-Print, 2020 | 52 | 2020 |
| Outsourcing of strategic resources and capabilities: opposing choices in the commercial aircraft manufacturing A Beaugency, ME Sakinç, D Talbot Journal of Knowledge Management 19 (5), 912-931, 2015 | 36 | 2015 |
| Executive compensation in Europe: Realized gains from stock-based pay P Kotnik, ME Sakinç, D Guduras Institute for New Economic Thinking Working Paper Series, 2018 | 32* | 2018 |
| Share repurchases in Europe a value extraction analysis ME Sakinç | 30 | 2017 |
| How financialization shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster productive model M Montalban, ME SakinÇ Université de Bordeaux GREThA UMR CNRS 5113, 35p, 2011 | 24 | 2011 |
| Financialization of the US pharmaceutical industry W Lazonick, Ö Tulum, M Hopkins, ME Sakinç, K Jacobson Institute for New Economic Thinking 2, 2019 | 22 | 2019 |
| L'industrie pharmaceutique: règles, acteurs et pouvoir MC Bélis-Bergouignan, M Montalban, ME Sakinç, A Smith HAL Post-Print, 2014 | 21 | 2014 |
| Do financial markets support innovation or inequity in the biotech drug development process? W Lazonick, ME Sakinç Workshop on Innovation and Inequality: Pharma and Beyond, Scuola Superiore …, 2010 | 19 | 2010 |
| US Pharma's Business Model: Why it is broken, and how it can be fixed W Lazonick, M Hopkins, K Jacobson, ME Sakinç, Ö Tulum The Routledge Handbook of the Political Economy of Science, 83-100, 2017 | 14 | 2017 |
| Life Sciences? How ‘Maximizing Shareholder Value’increases drug prices, restricts access, and stifles innovation W Lazonick, M Hopkins, K Jacobson, ME Sakinç, Ö Tulum UN Secretary-General’s High-Level Panel on Access to Medicines. https …, 2016 | 9 | 2016 |
| Make Passengers Safer? Boeing Just Made Shareholders Richer W Lazonick, ME Sakinç The American Prospect 31, 2019, 2019 | 6 | 2019 |
| Eylül’den Afganistan’a ABD İmparatorluğu ME Sakınç Ütopya Yayınları, 11 | 4 | 11 |
| Does acquisition lead to the growth of high-tech scale-ups? Evidence from Europe A Burger, T Hogan, P Kotnik, S Rao, ME Sakinç Research in International Business and Finance 64, 101820, 2023 | 3 | 2023 |
| The Impact of Acquisitions on Growth of European Hightech Entrepreneurial Firms P Kotnik, ME Sakinç ISIGrowth, 2018 | 3 | 2018 |
| Innovation or Financialization?: The Evoloution of the Systems-Integration Buisness Model at Airbus and Boeing ME Sakinç Bordeaux, 2016 | 2 | 2016 |
| ‘Maybe our children can see better days’: A brief history and analysis of farmers' cooperative organizations in Turkey ME Sakinc University of Massachusetts Lowell, 2009 | 2 | 2009 |
| The codetermination and financialization nexus–research on European firms E Gomec, ME Sakinc 32nd Annual Meeting, 2020 | 1 | 2020 |
